All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-10-31T09:58:32.000Z

ESH 2019 | What's new in flow cytometry assessment of MRD?

By Jacqueline Cloos
Featured
Jacqueline Cloos
Oct 31, 2019
Share:

Bookmark this article

The AML Global Portal were delighted to speak to Jacqueline Cloos, VU University Medical Center, Amsterdam, NL, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Jacqueline Cloos: What's new in flow cytometry assessment of MRD? She discusses how clinically validated MRD can be improved to act as a surrogate end-point in clinical trials.

What's new in flow cytometry assessment of MRD?

More about...
De novoDiseaseESH 2019Secondary

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
14 votes - 86 days left ...

Related articles

Add bookmark

Treatment of older or unfit patients with AML

Prof. Courtney DiNardo, MD Anderson Cancer Center, Houston, US, discussed the optimal treatment strategy for elderly or frail patients with AML at the 1st NCRI AML academy.

Nov 27, 2019
Add bookmark

Treatment of older or unfit patients with AML

Prof. Courtney DiNardo, MD Anderson Cancer Center, Houston, US, discussed the optimal treatment strategy for elderly or frail patients with AML at the 1st...

Nov 27, 2019
Add bookmark

Bispecific antibodies in lymphoma, myeloma and acute myeloid leukemia

Bispecific antibodies and chimeric antigen receptor T-cell therapy, are being investigated as agents to reduce the tumor load pre-SCT or post-SCT, with the aim of decreasing...

Oct 18, 2019
Add bookmark

Bispecific antibodies in lymphoma, myeloma and acute myeloid leukemia

Bispecific antibodies and chimeric antigen receptor T-cell therapy, are being investigated as agents to reduce the tumor load...

Oct 18, 2019

Newsletter

Subscribe to get the best content related to AML delivered to your inbox